Pharmaceuticals
Healthcare
Fireside-backed Ace Blend in advanced talks for Series B fundraise
Aces Intact Pvt Ltd, the operator of nutrition brand Ace Blend, is in advanced discussions to secure investments for its......
Healthcare
ChrysCap, two other PE firms vying for stake in domestic formulations maker
A clutch of private equity investors including ChrysCapital, Malaysia's Creador and Bahrain-headquartered Investcorp......
Healthcare
PE-backed drugmaker Brinton eyes fresh fundraise, hires banker
Pune-based drugmaker Brinton Pharmaceuticals Ltd is planning a fresh equity round of funding after a hiatus of nearly ......
Healthcare
True North bets on bulk drug maker Embio from seventh PE vehicle
Homegrown private equity firm True North is investing in Embio Ltd, as the bulk drug maker looks to expand its ......
Healthcare
Temasek-Novo consortium leads race for majority stake in nutraceuticals firm
A consortium comprising Singapore state investment firm Temasek Holdings and Danish investor Novo Holdings, the ......
Healthcare
Samarsh Capital, others hit jackpot as pharma portfolio firm eyes $182 mn tag
Small & medium enterprises (SME)-focused private equity firm Samarsh Capital that had led an investment round in a ......
Healthcare
Indian pharma firms set to dominate despite global risks: Panelists at VCCircle Healthcare Summit
Indian pharmaceuticals are set to dominate the global scene despite prevailing geopolitical uncertainty, said panelists ......
Healthcare
Sun Pharma's dementia drug slapped with ban in China
China's medicine regulator has ordered a halt to the import, sale and usage of a drug used to treat dementia ......
Healthcare
Bottomline: True North-controlled Integrace's revenue to shrink further before turnaround
True North and Temasek-backed drugmaker Integrace Pvt Ltd may see further decline in revenue this fiscal before seeing a......
Healthcare
Aurobindo Pharma to buy non-oncological business of Khandelwal Labs
Aurobindo Pharma Ltd is broadening its existing pain management portfolio with the acquisition of a non-oncological ......
